Any compound that inhibits one or more steps in the pathway leading to the synthesis of ergosterol.
ChEBI ID: 75282
| Member | Definition | Class |
|---|---|---|
| isavuconazole | A 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis. | isavuconazole |
| ravuconazole | A member of the class of triazoles that is 1-butyl-1H-1,2,4-triazole in which the butyl group is substituted at positions 2, 2, and 3 by hydroxy, 2,4-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively (the R,R stereoisomer). It exhibits antifungal activity by inhibition of 14alpha demethylase, an enzyme involved in sterol synthesis, resulting in lysis of the fungal cell wall and fungal cell death. (NCIO4) | ravuconazole |
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (2.50) | 18.2507 |
| 2000's | 81 (16.88) | 29.6817 |
| 2010's | 225 (46.88) | 24.3611 |
| 2020's | 162 (33.75) | 2.80 |
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|---|---|
| Trials | 44 (8.78%) | 5.53% |
| Reviews | 81 (16.17%) | 6.00% |
| Case Studies | 64 (12.77%) | 4.05% |
| Observational | 3 (0.60%) | 0.25% |
| Other | 309 (61.68%) | 84.16% |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 6.0081 | 1 | 1 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 18.9991 | 1 | 1 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 1.8999 | 1 | 1 |
| G | Vesicular stomatitis virus | Potency | 6.0081 | 1 | 1 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 6.0081 | 1 | 1 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 6.0081 | 1 | 2 |
| Interferon beta | Homo sapiens (human) | Potency | 6.0081 | 1 | 1 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 31.9798 | 2 | 2 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | IC50 | 11.0000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 1.0100 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 10.3700 | 1 | 1 |